{"transactions":[{"id":697716,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Line of Credit Convertible Notes","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":false,"price":10331275,"reported_value":10331275,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"Consists of $10,000,000 of principal and $331,275 of accrued interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of $10,000,000 of principal and $331,275 of accrued interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."}],"balance_after":0,"derivative":{"exercise_price":4.05,"exercise_date":"2025-12-31","expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":2550932},"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697715,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Line of Credit Convertible Notes","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":false,"price":95475705,"reported_value":95475705,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F1","text":"Consists of $91,000,000 in principal and $14,475,705 in accrued interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Consists of $91,000,000 in principal and $14,475,705 in accrued interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit.  Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027."}],"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2022-12-19","expiration_date":"2027-06-30","underlying":"Common Stock","underlying_shares":31825235},"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697714,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":true,"shares":2550932,"price":4.05,"value":10331274.6,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"balance_after":44713843,"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":697713,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-04T11:52:26.000Z","date":"2026-07-31","kind":"exercise","planned":false,"acquired":true,"shares":31825235,"price":3,"value":95475705.0,"ownership":{"direct":false,"nature":"Richard E. Uihlein Stock Trust"},"balance_after":42162911,"source":{"system":"sec-edgar","filing":"0001133416-26-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000065/form4.xml","form_type":"4"}},{"id":934498,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:44:18.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2026."}],"balance_after":60000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000020/form4.xml","form_type":"4"}},{"id":934497,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T21:44:18.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":13158,"price":3.04,"value":40000.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026."}],"balance_after":10332676,"source":{"system":"sec-edgar","filing":"0001133416-26-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000020/form4.xml","form_type":"4"}},{"id":1294691,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:09:18.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest 100% on December 31, 2025."}],"balance_after":60000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-25-000022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000022/form4.xml","form_type":"4"}},{"id":1294690,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-01-27T21:09:18.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":32520,"price":1.23,"value":39999.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024."}],"balance_after":10301271,"source":{"system":"sec-edgar","filing":"0001133416-25-000022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000022/form4.xml","form_type":"4"}},{"id":1655589,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2024-02-07T21:53:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest 100% on December 31, 2024."}],"balance_after":50000,"derivative":{"exercise_price":1.72,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-24-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000026/form4.xml","form_type":"4"}},{"id":1655588,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-02-07T21:53:47.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":23256,"price":1.72,"value":40000.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024."}],"balance_after":10268751,"source":{"system":"sec-edgar","filing":"0001133416-24-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000026/form4.xml","form_type":"4"}},{"id":1772729,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2023-06-30","expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772728,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.26,"exercise_date":"2023-03-31","expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772727,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2022-12-19","expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772726,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":330000,"derivative":{"exercise_price":5,"exercise_date":"2022-07-25","expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772725,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":false,"shares":1466204,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2017-06-22","expiration_date":"2023-12-23","underlying":"Common Stock","underlying_shares":1466204},"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772724,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":200000,"price":3,"value":600000.0,"ownership":{"direct":true},"balance_after":10235495,"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772723,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":200000,"price":3.26,"value":652000.0,"ownership":{"direct":true},"balance_after":10035495,"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772722,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":200000,"price":3,"value":600000.0,"ownership":{"direct":true},"balance_after":9835495,"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772721,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":170000,"price":5,"value":850000.0,"ownership":{"direct":true},"balance_after":9635495,"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":1772720,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-27T18:03:15.000Z","date":"2023-09-26","kind":"exercise","planned":false,"acquired":true,"shares":1466204,"price":5,"value":7331020.0,"ownership":{"direct":true},"balance_after":9466495,"source":{"system":"sec-edgar","filing":"0001133416-23-000075","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000075/form4.xml","form_type":"4"}},{"id":2042448,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:34:17.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest 100% on December 31, 2023."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-23-000008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000008/form4.xml","form_type":"4"}},{"id":2042447,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-01-30T21:34:17.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":36036,"price":1.11,"value":39999.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2023. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2023."}],"balance_after":7999291,"source":{"system":"sec-edgar","filing":"0001133416-23-000008","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000008/form4.xml","form_type":"4"}},{"id":2408766,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-02-08T14:25:01.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest 100% on December 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-22-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000043/form4.xml","form_type":"4"}},{"id":2408765,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-02-08T14:25:01.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":17677,"price":1.98,"value":35000.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022."}],"balance_after":7936677,"source":{"system":"sec-edgar","filing":"0001133416-22-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000043/form4.xml","form_type":"4"}},{"id":2426933,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Convertible Note","published_at":"2022-01-25T21:29:41.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":1841621,"price":10000000,"value":18416210000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Excludes interest that may accrue following issuance of the Note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Note is convertible upon 60 days prior written notice by the Noteholder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents the principal amount of the Convertible Note payable."}],"balance_after":10000000,"derivative":{"exercise_price":5.43,"expiration_date":"2025-12-20","underlying":"Common Stock","underlying_shares":1841621},"source":{"system":"sec-edgar","filing":"0001133416-22-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000026/form4.xml","form_type":"4"}},{"id":2563320,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2021-09-21T20:30:15.000Z","date":"2021-09-17","kind":"grant","acquired":true,"shares":1157407,"price":10000000,"value":11574070000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Excludes interest that may accrue following issuance of the Note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Note is convertible upon 60 days prior written notice by the noteholder."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Excludes interest that may accrue following issuance of the Note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents the principal amount of the note payable."}],"balance_after":10000000,"derivative":{"exercise_price":8.64,"expiration_date":"2025-09-17","underlying":"Common Stock","underlying_shares":1157407},"source":{"system":"sec-edgar","filing":"0000899243-21-036780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321036780/doc4.xml","form_type":"4"}},{"id":2745620,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2021-04-19T21:00:14.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":2000000,"price":10000000,"value":20000000000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Excludes interest that may accrue following issuance of the Note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In consideration for the Convertible Note, the Reporting Person loaned ten million dollars to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Note is convertible upon 60 days prior written notice by the noteholder."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Excludes interest that may accrue following issuance of the Note."}],"balance_after":10000000,"derivative":{"exercise_price":5,"expiration_date":"2025-04-16","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0000899243-21-016234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321016234/doc4.xml","form_type":"4"}},{"id":2769603,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:44.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":70000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-21-013817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013817/doc4.xml","form_type":"4"}},{"id":2769602,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:44.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest 100% on March 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-013817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013817/doc4.xml","form_type":"4"}},{"id":3035661,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-09T12:00:22.000Z","date":"2020-09-04","kind":"purchase","acquired":true,"shares":10000,"price":2.55,"value":25500.0,"ownership":{"direct":true},"balance_after":7893191,"source":{"system":"sec-edgar","filing":"0000899243-20-024606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320024606/doc4.xml","form_type":"4"}},{"id":3271211,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-02-14T13:01:16.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":18638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The options were issued pursuant to Galectin Therapeutics' Amended and Restated 2009 Incentive Stock Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options became fully vested on January 16, 2020."}],"balance_after":21362,"derivative":{"exercise_price":4.72,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":18638},"source":{"system":"sec-edgar","filing":"0000899243-20-004591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/doc4.xml","form_type":"4"}},{"id":3271210,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-02-14T13:01:16.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":46875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The options were issued pursuant to Galectin Therapeutics' Amended and Restated 2009 Incentive Stock Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options became fully vested on December 14, 2018."}],"balance_after":0,"derivative":{"exercise_price":2.39,"expiration_date":"2027-12-14","underlying":"Common Stock","underlying_shares":46875},"source":{"system":"sec-edgar","filing":"0000899243-20-004591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/doc4.xml","form_type":"4"}},{"id":3271209,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-14T13:01:16.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":18638,"price":4.72,"value":87971.36,"ownership":{"direct":true},"balance_after":7883191,"source":{"system":"sec-edgar","filing":"0000899243-20-004591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/doc4.xml","form_type":"4"}},{"id":3271208,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-14T13:01:16.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":46875,"price":2.39,"value":112031.25,"ownership":{"direct":true},"balance_after":7864553,"source":{"system":"sec-edgar","filing":"0000899243-20-004591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/doc4.xml","form_type":"4"}},{"id":3312695,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-01-13T23:09:25.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest 100% on December 31, 2020."}],"balance_after":45000,"derivative":{"exercise_price":2.86,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-20-001131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001131/doc4.xml","form_type":"4"}},{"id":3312694,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-13T23:09:25.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":12238,"price":2.86,"value":35000.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2020. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2020."}],"balance_after":7817678,"source":{"system":"sec-edgar","filing":"0000899243-20-001131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001131/doc4.xml","form_type":"4"}},{"id":3505080,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ed Uihlein Family Foundation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II.  There are no amendments to Table I."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II.  There are no amendments to Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation.  The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934."}],"balance_after":25700,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":1927},"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505079,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":15576322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II.  There are no amendments to Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."}],"balance_after":15576322,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":1168253},"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505078,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-29","kind":"exercise","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This Form 4 is being amended to correct certain dates contained in column 3 and column 6 of Table II.  There are no amendments to Table I."}],"balance_after":966204,"derivative":{"exercise_price":5,"exercise_date":"2017-06-22","expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505077,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":7710,"price":4.28,"value":32998.8,"ownership":{"direct":false,"nature":"By Ed Uihlein Family Foundation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation.  The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934."}],"balance_after":27710,"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505076,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":4672896,"price":4.28,"value":19999994.88,"ownership":{"direct":true},"balance_after":7801385,"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505075,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T22:10:17.000Z","date":"2019-05-29","kind":"exercise","acquired":true,"shares":500000,"price":5,"value":2500000.0,"ownership":{"direct":true},"balance_after":3128489,"source":{"system":"sec-edgar","filing":"0001179022-19-000038","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/edgar.xml","form_type":"4/A","original_submission_date":"2019-06-03"}},{"id":3505059,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ed Uihlein Family Foundation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation.  The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934."}],"balance_after":25700,"derivative":{"exercise_price":7,"exercise_date":"2019-11-23","expiration_date":"2026-06-03","underlying":"Common Stock","underlying_shares":1927},"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3505058,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":15576322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."}],"balance_after":15576322,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":1168253},"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3505057,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-21","kind":"exercise","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":966204,"derivative":{"exercise_price":5,"exercise_date":"2017-06-22","expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3505056,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":7710,"price":4.28,"value":32998.8,"ownership":{"direct":false,"nature":"By Ed Uihlein Family Foundation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation.  The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934."}],"balance_after":27710,"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3505055,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":4672896,"price":4.28,"value":19999994.88,"ownership":{"direct":true},"balance_after":7801385,"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3505054,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:28:22.000Z","date":"2019-05-29","kind":"exercise","acquired":true,"shares":500000,"price":5,"value":2500000.0,"ownership":{"direct":true},"balance_after":3128489,"source":{"system":"sec-edgar","filing":"0001179022-19-000032","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/edgar.xml","form_type":"4"}},{"id":3559483,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-09T20:02:57.000Z","date":"2019-04-09","kind":"purchase","acquired":true,"shares":20700,"price":4.8237,"value":99850.59,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $4.80 to $4.85. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":2628489,"source":{"system":"sec-edgar","filing":"0001179022-19-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000031/edgar.xml","form_type":"4"}},{"id":3560528,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-08T20:31:14.000Z","date":"2019-04-05","kind":"purchase","acquired":true,"shares":21000,"price":4.8082,"value":100972.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $4.789 to $4.810. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":2607789,"source":{"system":"sec-edgar","filing":"0001179022-19-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000029/edgar.xml","form_type":"4"}},{"id":3681385,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-31T15:55:03.000Z","date":"2019-01-29","kind":"purchase","acquired":true,"shares":48500,"price":4.871,"value":236243.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.00. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 is being amended to correct footnotes  (1) and (2) for the purchase transactions on January 28, 2019 and January 29, 2019, which footnotes incorrectly stated that the shares were sold in multiple transactions, but should have stated that the shares were purchased in multiple transactions."}],"balance_after":2586789,"source":{"system":"sec-edgar","filing":"0001179022-19-000023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000023/edgar.xml","form_type":"4/A","original_submission_date":"2019-01-30"}},{"id":3681384,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-31T15:55:03.000Z","date":"2019-01-28","kind":"purchase","acquired":true,"shares":3000,"price":4.7717,"value":14315.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were purchased in multiple transactions at prices ranging from $4.77 to $4.78. This amount represents the weighted average purchase price of such transactions. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This Form 4 is being amended to correct footnotes  (1) and (2) for the purchase transactions on January 28, 2019 and January 29, 2019, which footnotes incorrectly stated that the shares were sold in multiple transactions, but should have stated that the shares were purchased in multiple transactions."}],"balance_after":2538289,"source":{"system":"sec-edgar","filing":"0001179022-19-000023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000023/edgar.xml","form_type":"4/A","original_submission_date":"2019-01-30"}},{"id":3682709,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-30T22:31:04.000Z","date":"2019-01-29","kind":"purchase","acquired":true,"shares":48500,"price":4.871,"value":236243.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.75 to $5.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":2586789,"source":{"system":"sec-edgar","filing":"0001179022-19-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000021/edgar.xml","form_type":"4"}},{"id":3682708,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-30T22:31:04.000Z","date":"2019-01-28","kind":"purchase","acquired":true,"shares":3000,"price":4.7717,"value":14315.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were sold in multiple transactions at prices ranging from $4.77 to $4.78. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":2538289,"source":{"system":"sec-edgar","filing":"0001179022-19-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000021/edgar.xml","form_type":"4"}},{"id":3691965,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-01-18T22:20:55.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on January 16, 2020."}],"balance_after":40000,"derivative":{"exercise_price":4.72,"expiration_date":"2029-01-16","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179022-19-000019","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000019/edgar.xml","form_type":"4"}},{"id":3691964,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-01-18T22:20:55.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":7415,"price":4.72,"value":34998.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2019.  Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2019."}],"balance_after":2535289,"source":{"system":"sec-edgar","filing":"0001179022-19-000019","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000019/edgar.xml","form_type":"4"}},{"id":4128826,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-12-18T21:10:41.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":46875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest 100% on December 14, 2018."}],"balance_after":46875,"derivative":{"exercise_price":2.39,"expiration_date":"2027-12-14","underlying":"Common stock","underlying_shares":46875},"source":{"system":"sec-edgar","filing":"0001179022-17-000075","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902217000075/edgar.xml","form_type":"4"}},{"id":4128825,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":26780,"kind":"person","name":"Uihlein Richard E","position":1,"cik":"0001694903","reported_name":"Uihlein Richard E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-18T21:10:41.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":14644,"price":2.39,"value":34999.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2018.  Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018."}],"balance_after":2524553,"source":{"system":"sec-edgar","filing":"0001179022-17-000075","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902217000075/edgar.xml","form_type":"4"}}]}